# Vaderis Therapeutics funding rounds and investors

As of 14 Oct 2026, Vaderis Therapeutics has raised $152M across 1 verified round on record; latest: $152 million Series B led by Goldman Sachs Alternatives and TCGX, announced 11 Aug 2026.

Breakthrough therapies for patients with Hereditary Hemorrhagic Telangiectasia (HHT) and other rare vascular diseases.

Website: https://vaderis.com  
Headquarters: Basel, Switzerland  
Page: https://fireround.dev/companies/vaderis.com

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2026-08-11 | Series B | $152 million | Goldman Sachs Alternatives, TCGX | Droia, EQT Life Sciences, Kalehua Capital, Medicxi, Omega Funds, Perceptive Advisors | [prnewswire.com](https://www.prnewswire.com/news-releases/vaderis-therapeutics-announces-oversubscribed-152-million-series-b-financing-and-initiation-of-the-global-phase-3-heroic-study-of-engasertib-for-hereditary-hemorrhagic-telangiectasia-302845188.html) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.